Abstract
BackgroundDrug resistance of paclitaxel (TAX), the first-line chemotherapy drug for breast cancer, was reported to develop in 90% of patients with breast cancer, especially metastatic breast cancer. Investigating the mechanism of TAX resistance of breast cancer cells and developing the strategy improving its therapeutic efficiency are crucial to breast cancer cure.Methods and ResultsWe here report an elegant nanoparticle (NP)-based technique that realizes efficient breast cancer treatment of TAX. Using lentiviral vector-mediated gene knockdown, we first demonstrated that TAX therapeutic efficiency was closely correlated with metadherin (MTDH) gene expression in breast cancer cell lines. This finding was also supported by efficacy of TAX treatment in breast cancer patients from our clinical studies. Specifically, TAX treatment became more effective when MTDH expression was decreased in MCF-7 cancer cells by the blocking nuclear factor-kappa B (NF-κB) pathway. Based on these findings, we subsequently synthesized a polymeric NP that could co-deliver MTDH-small interfering RNA (MTDH–siRNA) and TAX into the breast cancer tumors in tumor-bearing mice. The NPs were composed of a cationic copolymer, which wrapped TAX in the inside and adsorbed the negatively charged siRNA on their surface with high drug-loading efficiency and good stability.ConclusionsNP-based co-delivery approach can effectively knock down the MTDH gene both in vitro and in vivo, which dramatically inhibits breast tumor growth, achieving effective TAX chemotherapy treatment without overt side effects. This study provides a potential therapeutic strategy for the treatment of a wide range of solid tumors highly expressing MTDH.
Highlights
Drug resistance of paclitaxel (TAX), the first-line chemotherapy drug for breast cancer, was reported to develop in 90% of patients with breast cancer, especially metastatic breast cancer
NP-based co-delivery approach can effectively knock down the MTDH gene both in vitro and in vivo, which dramatically inhibits breast tumor growth, achieving effective the opposite. Figure S6. Paclitaxel (TAX) chemotherapy treatment without overt side effects
Based on Effect of MTDH expression on MCF-7 breast cancer cells To investigate the effect of MTDH expression in breast cancer cell lines, we first performed Real-time polymerase chain reaction (RT-PCR) tests on our modified MCF-7 breast cancer cells
Summary
Drug resistance of paclitaxel (TAX), the first-line chemotherapy drug for breast cancer, was reported to develop in 90% of patients with breast cancer, especially metastatic breast cancer. The key options in breast cancer treatment so far include surgery, chemotherapy, radiotherapy, and molecular targeted therapy [1]. Out of these approaches, chemotherapy appears to be the most widely adopted. Yang et al Breast Cancer Research (2018) 20:113 the Erk/nuclear factor-kappa B (Erk/NF-κB) pathway and decreasing cleavage of caspase-3 [11,12,13,14] Based on these findings, we explored the relationship between MTDH gene expression and TAX resistance in breast cancer cell lines as well as the effect of MTDH knockdown on TAX therapeutic efficiency. For in vivo therapeutic study, we employed targeted nanocarriers to co-deliver anti-MTDH small interfering RNA (siRNA) (for tumor-specific silence of MTDH gene) and TAX drug
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
